This work ultimately led to the creation of Fountain Therapeutics, where he is a co-founder – and continues to drive a significant amount of the research conducted at his Stanford lab.

When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace cytogenetic tests to diagnose cancers and rare diseases.

Valneva makes vaccines from inactivated viruses that are killed with chemicals. Jonas Salk and other early vaccine makers found this recipe to work well. Chinese vaccine makers already have three such coronavirus vaccines in Phase 3 trials, but Dr. Lingelbach still sees an opportunity for Valneva making its own.

Patrick Soon-Shiong knows when he realized that the Covid-19 pandemic was going to pose a serious threat. It was February 24, and the part-owner of the L.A. Lakers was at the Staples Center in Los Angeles for Kobe Bryant’s memorial service.

“Empowering” natural killer (NK) cells to destroy tumors could cut the cost of cell therapies, according to a company developing the technology. Acepodia has started Phase I trials of its lead drug candidate, a cancer treatment based on a new cell therapy platform. Antibody Cell Conjugation (ACC) uses “molecular Velcro” to attach tumor-fighting antibodies to the surface of proprietary NK cells.

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in areas such as oncology and autoimmunity.